Title

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Authors

Khalid El Bairi, Université Mohammed Premier Oujda
Khalid El Bairi, Université Mohammed Premier Oujda
Harry R. Haynes, Great Western Hospital
Elizabeth Blackley, Peter Maccallum Cancer Centre
Elizabeth Blackley, Peter Maccallum Cancer Centre
Susan Fineberg, Albert Einstein College of Medicine of Yeshiva University
Jeffrey Shear, Ardsley High School
Sophia Turner, Independent Cancer Patients' Voice
Sophia Turner, Independent Cancer Patients' Voice
Juliana Ribeiro de Freitas, Universidade Federal da Bahia
Daniel Sur, Universitatea de Medicina si Farmacie Iuliu Hatieganu din Cluj-Napoca
Luis Claudio Amendola, Brazilian Society of Surgical Oncology
Masoumeh Gharib, Mashhad University of Medical Sciences, School of Medicine
Amine Kallala, Université de Tunis El Manar, Hôpital Charles Nicolle
Amine Kallala, Université de Tunis El Manar, Hôpital Charles Nicolle
Indu Arun, Tata Medical Center
Farid Azmoudeh-Ardalan, Imam Khomeini Hospital
Farid Azmoudeh-Ardalan, Imam Khomeini Hospital
Luciana Fujimoto, Amazon Federal Rural University
Luz F. Sua, Universidad Icesi
Luz F. Sua, Universidad Icesi
Shi Wei Liu, Sichuan Cancer Hospital and Institute
Huang Chun Lien, National Taiwan University Hospital
Pawan Kirtani, Manipal Hospitals
Pawan Kirtani, Manipal Hospitals
Marcelo Balancin, Universidade de São Paulo
Marcelo Balancin, Universidade de São Paulo
Hicham El Attar, Annasr Pathology Center
Hicham El Attar, Annasr Pathology Center
Prerna Guleria, Army Hospital (Research & Referral)
Wenxian Yang, Aginome Scientific
Emad Shash, Cairo University
Emad Shash, Cairo University

Publication Date

12-1-2021

Document Type

Article

Publication Title

npj Breast Cancer

Abstract

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.

To view the document, please click the DOI link after the APA Citation.

Share

COinS